Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors
作者:Jean-Yves Winum、Daniela Vullo、Angela Casini、Jean-Louis Montero、Andrea Scozzafava、Claudiu T. Supuran
DOI:10.1021/jm021124k
日期:2003.5.1
(steroidal), and sugar moieties in their molecules has been synthesized and assayed as inhibitors of the zincenzymecarbonicanhydrase (CA), and more precisely of the cytosolic isozymesCAI andII, and the transmembrane, tumor-associated isozymesCA IX. Some of these compounds were previously reported to act as inhibitors of steroid sulfatases, among which estrone sulfatase (ES) and dehydroepiandrosterone
A method for controlling estrogen production comprising administering a ring system compound comprising a sulphamic acid ester group; wherein said compound is an inhibitor of an enzyme having steroid sulphatase activity (EC 3.1.6.2); and wherein if the sulphamic acid ester group of said compound is replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (EC 3.1.6.2) at a pH 7.4 and 37° C. it provides a K
m
value of less than 50 &mgr;M. A method to target the estrogen metabolic pathway comprising administering a ring system compound comprising a sulphamic acid ester group; wherein said compound is an inhibitor of an enzyme having steroid sulphatase activity (EC 3.1.6.2); and wherein if the sulphamic acid ester group of said compound is replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (EC 3.1.6.2) at a pH 7.4 and 37° C. it provides a K
m
value of less than 50 &mgr;M.
Use of sulphamate derivatives as steroid sulphatase inhibitors
申请人:IMPERIAL COLLEGE OF SCIENCE
TECHNOLOGY AND MEDICINE
公开号:EP0928609A2
公开(公告)日:1999-07-14
The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula
wherein each of R1 and R2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; and wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2); wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a Km value of less than 50 µM; and wherein at least one of R1 and R2 is H.
Use of a ring system compound comprising a sulphamic acid ester group for the manufacture of medicaments for the control of oestrogen production
申请人:Sterix Limited
公开号:EP0982032A2
公开(公告)日:2000-03-01
The present invention provides use of a ring system compound for the manufacture of a medicament to control oestrogen production, and/or use of a ring system compound for the manufacture of a medicament to target the oestrogen metabolic pathway, wherein ring system compound comprises a sulphamic acid ester group; wherein said compound is an inhibitor of an enzyme having steroid sulphatase activity (EC 3.1.6.2); and wherein if the sulphamic acid ester group of said compound is replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (EC 3.1.6.2) at a pH 7.4 and 37°C it provides a Km value of less than 50µm.
Estrane sulphamate derivatives as steroid sulphatase inhibitors
申请人:Sterix Limited
公开号:EP1099706A2
公开(公告)日:2001-05-16
There is provided a purified compound of the formula
wherein R1 and R2 are H; and wherein the group Polycycle is a residue of an oestrogen wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2); wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a Km value of less than 50 µM.